Intelligence Dashboards

Search and filter 149,000+ clinical trials by drug, sponsor, phase, and condition.

10 years of FDA novel drug approvals (2016-2025) with designation data: first-in-class, orphan drug, breakthrough therapy, and more.

Upcoming FDA target action dates. Know when approval decisions are expected.

Track Phase 1-4 trial activity by company. See who has the strongest clinical pipeline.

Any company's pipeline by therapeutic area and phase — now with an indication × mechanism heatmap, forward catalysts, and per-asset tearsheets.

Who's competing in each indication — a company × mechanism heatmap plus a "by line of therapy" cut, forward catalysts, and click-any-cell asset tearsheets.

Pick a mechanism family (HER2, ADCs, T-cell engagers…) and see every drug against that target across all indications — drugs × indications, with catalysts and tearsheets.

Rising and falling indications based on trial activity over time.

FDA-approved biosimilars, reference products, and market leaders.

Blockbuster drugs losing exclusivity 2026–2032. Actual company revenue from SEC filings. Patent dates from Orange Book + manual overrides.

CMS Medicare Part D spending for drugs losing exclusivity 2026–2030. Historical cliff case studies.

Trial activity and competition by indication. Identify concentrated vs fragmented markets.

Competitive density heatmap across all therapeutic areas.

Head-to-head comparison of any two company portfolios.

Browse the indication taxonomy and see coverage metrics.